Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We
demonstrated in vitro synergism between histone deacetylase inhibitors and DNA …

Primary cutaneous T-cell lymphomas (PCTCL) are the most common types of cutaneous
lymphomas, with Mycosis fungoides as the most frequent subtype. Besides early stages …

The majority of historical therapies for managing T-cell lymphomas (TCLs) have consisted of
T-cell–depleting strategies. Unfortunately, these forms of therapies can hamper the ability to …

This chapter is focused on the role of epigenetic agents in the treatment of lymphoid
malignancies. The study of epigenetics is a complex topic that has significantly evolved over …

The discovery of new therapeutic agents followed by the subsequent development of novel
drug–drug combinations has been one of the most exciting areas in cancer medicine. This …